(NASDAQ: RNXT) Renovorx's forecast annual revenue growth rate of 162.34% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.4%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.27%.
Renovorx's revenue in 2026 is $1,976,000.On average, 6 Wall Street analysts forecast RNXT's revenue for 2026 to be $147,438,103, with the lowest RNXT revenue forecast at $122,210,708, and the highest RNXT revenue forecast at $166,527,885. On average, 6 Wall Street analysts forecast RNXT's revenue for 2027 to be $565,833,771, with the lowest RNXT revenue forecast at $199,021,130, and the highest RNXT revenue forecast at $1,095,834,713.
In 2028, RNXT is forecast to generate $1,760,276,460 in revenue, with the lowest revenue forecast at $956,068,627 and the highest revenue forecast at $2,247,900,793.